Healthcare Value Capital, LLC has urged the board of Novelion Therapeutics Inc. (NasdaqGS: NVLN) to explore strategic alternatives. Novelion revealed through an amendment to a SEC 13-D filing that Healthcare Value Capital sent a letter to Novelion's board urging the exploration of strategic alternatives. Healthcare Value Capital has a 9.5% stake in Novelion. "We would welcome the opportunity to meet with you and management to discuss our thoughts on an immediate program to decisively and permanently normalize costs as well as the relative merits, timing and terms for the strategic alternatives available to Novelion," Healthcare Venture Capital's letter said.